However, it has also been shown that even though BTZ induces neuropathy in 31–64% of the patients, there is full neurological recovery in 86% of the cases, because BTZ binds reversibly to the proteasome and after treatment all nucleated, surviving cells can resynthesize new proteasomes [60]. This evidence concerns the gene CASC3 and neuropathy.